Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Antje WickOliver BährMartin SchulerKristoffer Staal RohrbergSant P ChawlaFilip JankuDavid SchiffVolker HeinemannYoshitaka NaritaHeinz-Josef LenzMasafumi IkedaYuichi AndoWolfgang WickJoachim P SteinbachMichael C BurgerKatharina Johanna WengerUlrik N LassenKamalesh K SankhalaCristiana RoggiaIsabelle GenvresseCatya MunhozChristine RentzschSusanne ReschkeSimon LangerMarkus WagnerStefan KaulfussCharles CaiEleni LagkadinouMichael JeffersCarol PeñaGhazaleh TabatabaiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
BAY1436032 was well tolerated and showed evidence of target inhibition and durable objective responses in a small subset of subjects with LGG.
Keyphrases